Parkinson's & Alzheimer's Flashcards
4 Major clinical features of Parkinson’s
- Bradykinesia, 2. muscular rigidty (cogwheel), 3. resting tremor, 4. impairment of postural balance/gait
Parkinson’s etiology
- Idiopathic, 2. Parkin (alpha-synuclein gene), 3. MPTP
Drugs and DA target
- Increase brain dopamine levels
- Inhibit dopamine metabolism in the brain (MAO-B & COMT)
- Stimulate brain DA D2 receptors
- In the periphery, inhibit the conversion of L-dopa to dopamine & Inhibit the metabolism of L-dopa (COMT)
Peripheral effects of L-DA
N/V
Pt came in taking haloperidol and complaining of Parkison-like sxs, can you treat her with some L-dopa?
No mami
Is L-dopa a good mono drug choice for long-term use
No, it will eventually lose it’s affect because DA neurons will continue to degenerate
Why combine carbidopa and L-dopa
Carbidopa inhibts dopa-decarboxlase –> conversion of L-dopa to DA is inhibited in periphery –> decrease dose of L-dopa needed and decrease peripheral effects
Which SE more common with L-dopa/carbidopa combination and can be treated by reducing L-dopa
Dyskinesias
On-Off phenomenon
Fluctuations in clinical response in patients on successful l-dopa therapy
“On” = Improved mobility (w/dyskinesias)
“Off” = Akinesia due to falling drug levels
Rescue for on and off phenomenon
Apomorphine
L-dopa drug interactions w/
MAO-AI (hypertensive crisis); pyridoxine/vitB6 - increase peripheral metabolism of I-dopa
MAOI for parkinson’s inhibits MAO-A or B?
BB
COMT inhibitor in CNS and peripheral
Tolcapone
COMT inhibitor in pierphery only
Entacapone
SE: orange color in urine
COMT inhibitors (Tolcapone, entacapone)